FI913511A0 - Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi

Info

Publication number
FI913511A0
FI913511A0 FI913511A FI913511A FI913511A0 FI 913511 A0 FI913511 A0 FI 913511A0 FI 913511 A FI913511 A FI 913511A FI 913511 A FI913511 A FI 913511A FI 913511 A0 FI913511 A0 FI 913511A0
Authority
FI
Finland
Prior art keywords
activator
targeting moiety
prodrug
target tissue
preparing
Prior art date
Application number
FI913511A
Other languages
English (en)
Swedish (sv)
Other versions
FI97692B (fi
FI97692C (fi
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Cabe Richard Mc
Nicholas Pomato
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI913511(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI913511A0 publication Critical patent/FI913511A0/fi
Publication of FI97692B publication Critical patent/FI97692B/fi
Application granted granted Critical
Publication of FI97692C publication Critical patent/FI97692C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI913511A 1989-01-23 1991-07-22 Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi FI97692C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23
US30099989 1989-01-23
US9000503 1990-01-23
PCT/US1990/000503 WO1990007929A1 (en) 1989-01-23 1990-01-23 Site specific in-vivo activation of therapeutic drugs

Publications (3)

Publication Number Publication Date
FI913511A0 true FI913511A0 (fi) 1991-07-22
FI97692B FI97692B (fi) 1996-10-31
FI97692C FI97692C (fi) 1997-02-10

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913511A FI97692C (fi) 1989-01-23 1991-07-22 Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi

Country Status (12)

Country Link
EP (1) EP0454783B1 (fi)
JP (1) JP3273608B2 (fi)
KR (1) KR0185967B1 (fi)
AT (1) ATE123414T1 (fi)
AU (1) AU648015B2 (fi)
CA (1) CA2025899A1 (fi)
DE (1) DE69019959T2 (fi)
DK (1) DK0454783T3 (fi)
ES (1) ES2075893T3 (fi)
FI (1) FI97692C (fi)
NO (1) NO912864L (fi)
WO (1) WO1990007929A1 (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DE69034042T2 (de) * 1989-08-02 2003-07-17 Mitra Medical Technology Ab Lu System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU4663493A (en) * 1992-07-06 1994-01-31 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
EP0806964B1 (en) * 1994-12-23 2002-08-14 AstraZeneca AB Chemical compounds
KR19990036383A (ko) 1995-08-16 1999-05-25 크로우 캐씨 엘 화학적 화합물
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
WO1989000050A1 (en) * 1987-07-02 1989-01-12 Akzo N.V. Antigen recognized by mca 16-88
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
ES2075893T3 (es) 1995-10-16
EP0454783B1 (en) 1995-06-07
JPH04503068A (ja) 1992-06-04
AU648015B2 (en) 1994-04-14
DK0454783T3 (da) 1995-10-16
KR910700072A (ko) 1991-03-13
AU5039790A (en) 1990-08-13
EP0454783A1 (en) 1991-11-06
EP0454783A4 (en) 1992-01-15
DE69019959T2 (de) 1995-10-05
FI97692B (fi) 1996-10-31
NO912864L (no) 1991-09-19
KR0185967B1 (ko) 1999-05-01
WO1990007929A1 (en) 1990-07-26
JP3273608B2 (ja) 2002-04-08
CA2025899A1 (en) 1990-07-24
DE69019959D1 (de) 1995-07-13
NO912864D0 (no) 1991-07-22
FI97692C (fi) 1997-02-10
ATE123414T1 (de) 1995-06-15

Similar Documents

Publication Publication Date Title
FI913511A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
NO842291L (no) Fremgangsmaate for fremstilling av orale antidiabetiske substanser.
PT75208A (en) Process for preparing of a eucalyptol composition
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
OA08170A (fr) Procédé de solubilisation de principes actifs et compositions pharmaceutiques ainsi obtenues.
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
NO158004C (no) Fremgangsmaate for fremstilling av et preparat med cytolytisk aktivitet.
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
NO156900B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater.
GB2008944A (en) Copper compositions for topical application in the treatment of copper deficiency in animals
EP0009636A3 (en) 3-chloro-6-hydroxy-5-methylbenzoic acid derivative, corresponding pharmaceutical preparations, growth promoting compositions, the use of the compounds in the treatment and prophylaxis of diseases and for promoting growth of certain animals, and their manufacture
FI860816A (fi) Menetelmä terapeuttisesti käyttökelpoisten polyprenyyliyhdisteiden valmistamiseksi
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
ATE2746T1 (de) Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
FR2664594B1 (fr) Polymethylene-imines disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
ES469749A1 (es) Un procedimiento para la preparacion de una formulacion far-maceutica de una droga de notroimidazol.
ATE28384T1 (de) Medizinisches verfahren und zubereitung.
KR920700633A (ko) 열 및 빛의 방사선 때문에 일어난 자동면역 질병 및 피부병에 대한 예방 및 치료 방법
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
GR1001344B (el) Νέοι υδατοδιαλυτοί πολυμερικοί ρυ?μιστές ανάπτυξης των φυτών: σύν?εση και χρήση.
MX9207313A (es) Novedosa 10-hidroxi feofitina a.
KR890007737A (ko) 진토작용을 하는 약제

Legal Events

Date Code Title Description
BB Publication of examined application